MCID: LNG039
MIFTS: 57

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Lung 12 71
Squamous Cell Lung Carcinoma 6 17
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3907
NCIt 50 C3493
SNOMED-CT 67 254634000
UMLS 71 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and adenocarcinoma. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Endometrial cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Nedaplatin and afatinib have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and endothelial, and related phenotype is pigmentation.

Wikipedia : 74 Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC).... more...

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 358)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.4 TUG1 TP53 SOX2-OT PIK3CA FGFR2 EGFR
2 adenocarcinoma 32.0 TP53 PIK3CA KRAS FGFR2 EGFR ALK
3 small cell carcinoma 31.4 TP53 KRAS EGFR ALK
4 lung cancer susceptibility 3 31.3 TUG1 TP53 SFTA1P PIK3CA NPTN-IT1 MEG3
5 in situ carcinoma 31.1 TP53 PIK3CA EGFR
6 retinitis pigmentosa 11 31.0 TUG1 TP53 PVT1 EGFR ALK
7 pleomorphic carcinoma 30.9 TP53 EGFR ALK
8 lung carcinoma in situ 30.8 KRAS EGFR ALK
9 lung adenoma 30.8 TP53 KRAS EGFR
10 lung non-squamous non-small cell carcinoma 30.8 KRAS EGFR ALK
11 lung benign neoplasm 30.8 TP53 KRAS EGFR
12 adenosquamous carcinoma 30.8 TP53 PIK3CA KRAS EGFR
13 thyroid gland anaplastic carcinoma 30.7 TP53 PIK3CA EGFR ALK
14 skin melanoma 30.7 TP53 PIK3CA KRAS EGFR ALK
15 breast adenocarcinoma 30.7 TP53 PIK3CA KRAS EGFR
16 adenoid cystic carcinoma 30.7 TP53 PIK3CA KRAS EGFR
17 small cell cancer of the lung 30.7 TUG1 TP53 PIK3CA EGFR CCAT2 ALK
18 pancreatic ductal adenocarcinoma 30.6 TP53 PVT1 KRAS EGFR
19 malignant pleural mesothelioma 30.6 TP53 PVT1 EGFR
20 colon adenocarcinoma 30.6 TP53 PIK3CA KRAS EGFR
21 colorectal adenocarcinoma 30.5 TP53 KRAS EGFR
22 kidney cancer 30.4 TP53 PVT1 PIK3CA MEG3 EGFR
23 neuroblastoma 30.4 TP53 SNHG1 PIK3CA MEG3 EGFR ALK
24 glioblastoma 30.3 TUG1 TP53 PIK3CA MEG3 FGFR2 EGFR
25 intrahepatic cholangiocarcinoma 30.3 TUG1 TP53 KRAS FGFR2 EGFR CCAT2
26 cholangiocarcinoma 30.3 TUG1 TP53 SOX2-OT PIK3CA KRAS FGFR2
27 melanoma 30.2 TP53 SOX2-OT PVT1 PIK3CA MEG3 KRAS
28 leukemia, acute myeloid 30.2 TUG1 TP53 PIK3CA MEG3 KRAS EGFR
29 glioma 30.1 TP53 PVT1 PIK3CA MEG3 EGFR CCAT2
30 renal cell carcinoma, nonpapillary 30.1 TUG1 TP53 PVT1 PIK3CA NPTN-IT1 EGFR
31 nasopharyngeal carcinoma 30.0 TP53 PVT1 PIK3CA NPTN-IT1 MEG3 FGFR2
32 lung cancer 29.5 TUG1 TP53 TERC SOX2-OT SNHG1 PVT1
33 gastric cancer 29.2 TUG1 TP53 TERC SOX2-OT SNHG1 SFTA1P
34 lung occult squamous cell carcinoma 11.3
35 lung mixed small cell and squamous cell carcinoma 11.3
36 adult teratoma 10.6 TP53 FGFR2
37 esophagus adenocarcinoma 10.6 TP53 FGFR2 EGFR
38 acanthoma 10.6 TP53 PIK3CA FGFR2
39 signet ring lung adenocarcinoma 10.6 EGFR ALK
40 esophagus verrucous carcinoma 10.6 TP53 EGFR
41 vulvar disease 10.6 TP53 PIK3CA EGFR
42 skin papilloma 10.6 TP53 KRAS EGFR
43 endometrial adenocarcinoma 10.6 TP53 KRAS FGFR2 EGFR
44 esophageal basaloid squamous cell carcinoma 10.6 TP53 EGFR
45 paronychia 10.6 KRAS EGFR ALK
46 estrogen-receptor positive breast cancer 10.6 TP53 PIK3CA FGFR2 EGFR
47 parameningeal embryonal rhabdomyosarcoma 10.6 TP53 PIK3CA ALK
48 bile duct adenocarcinoma 10.6 TP53 KRAS FGFR2 EGFR
49 respiratory system benign neoplasm 10.6 TP53 KRAS EGFR
50 uterine carcinosarcoma 10.6 TP53 PIK3CA FGFR2 EGFR

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.02 ALK EGFR FGFR2 KRAS TP53

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nedaplatin Approved, Investigational Phase 4 95734-82-0
2
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
3
Apatinib Phase 4 811803-05-1
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Vinblastine Approved Phase 3 865-21-4 13342 241903
8
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
9
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
10
Ipilimumab Approved Phase 3 477202-00-9
11
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
12
Palbociclib Approved, Investigational Phase 2, Phase 3 571190-30-2 11431660 5005498 5330286
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
15
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
16
Tirapazamine Investigational Phase 3 27314-97-2
17
Iniparib Investigational Phase 3 160003-66-7
18
Rilotumumab Investigational Phase 2, Phase 3 872514-65-3
19 Etoposide phosphate Phase 3
20 Alkylating Agents Phase 3
21 Endostar protein Phase 3
22 Endostatins Phase 3 71581480
23 Hematinics Phase 3
24 Epoetin alfa Phase 3 113427-24-0
25 Immunoglobulin G Phase 2, Phase 3
26 Protein Kinase Inhibitors Phase 2, Phase 3
27 Antineoplastic Agents, Immunological Phase 2, Phase 3
28 Angiogenesis Inhibitors Phase 3
29 Anti-Bacterial Agents Phase 3
30
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
31 Cyclooxygenase Inhibitors Phase 3
32 Cyclooxygenase 2 Inhibitors Phase 3
33 Antirheumatic Agents Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Analgesics Phase 3
36 Anti-Inflammatory Agents, Non-Steroidal Phase 3
37 Immunoglobulins Phase 2, Phase 3
38 Antibodies Phase 2, Phase 3
39 Antibodies, Monoclonal Phase 2, Phase 3
40 Immunoglobulins, Intravenous Phase 2, Phase 3
41
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
42
Clarithromycin Approved Phase 2 81103-11-9 84029
43
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
44
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
45
Isotretinoin Approved Phase 2 4759-48-2 5538 5282379
46
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2, 11096-26-7
49
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
50
Lomustine Approved, Investigational Phase 2 13010-47-4 3950

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above Unknown status NCT03725423 Phase 4 Apatinib
2 Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
3 An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Recruiting NCT04132102 Phase 4 Afatinib
4 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
5 Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
6 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase Ⅲ Study Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
7 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
8 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
9 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
10 A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
11 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
12 RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY Completed NCT00002623 Phase 3 carboplatin;cisplatin
13 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
14 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
15 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
16 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
17 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
18 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
19 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
20 Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
21 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
22 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
23 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
24 A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) Active, not recruiting NCT02785952 Phase 3
25 A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study) Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
26 A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
27 A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
28 Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) Active, not recruiting NCT03150875 Phase 3 Docetaxel
29 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
30 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
31 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
32 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
33 A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Terminated NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
34 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
35 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
36 Photodynamic Therapy for the Prevention of Lung Cancer (PEARL) Withdrawn NCT03346304 Phase 2, Phase 3
37 Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
38 First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
39 A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
40 A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
41 A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
42 Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial Unknown status NCT01660399 Phase 2 Boanmycin;Docetaxel
43 A Phase I/II Study of Anlotinib Combined With Platinum-based Chemotherapy as the First-line Treatment of Patients With Locally Advanced or Advanced Non-Small Cell Lung Cancer Unknown status NCT03636685 Phase 1, Phase 2 Anlotinib combined with pemetrexed and carboplatin, phase I;Anlotinib combined with paclitaxel and carboplatin, phase I;Anlotinib combined with pemetrexed and carboplatin, phase II;Anlotinib combined with paclitaxel and carboplatin, phase II
44 A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure Unknown status NCT02852083 Phase 2 Pioglitazone;nivolumab;Treosulfan;Clarithromycin
45 A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy Unknown status NCT01969955 Phase 2 nanoparticle albumin-bound paclitaxel
46 An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer Unknown status NCT02009605 Phase 2 Icotinib
47 Phase II Study of Afatinib Plus Chemotherapy in Patients With Esophageal and Lung Squamous Cell Carcinoma Unknown status NCT03486509 Phase 2 Afatinib
48 A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma Unknown status NCT02428764 Phase 2 Nimotuzumab;Gemcitabine;Carboplatin
49 A Phase II Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Docetaxel Consolidation in Patients With Inoperable Stage IIIA/B Squamous Cell Lung Cancer Unknown status NCT02787473 Phase 2 pemetrexed;cisplatin;docetaxel
50 A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers Unknown status NCT02423590 Phase 2 Apatorsen (OGX-427);Gemcitabine;Carboplatin

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Anatomical Context for Lung Squamous Cell Carcinoma

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

40
Lung, Lymph Node, Endothelial, T Cells, Thyroid, Prostate, Skin

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 1966)
# Title Authors PMID Year
1
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. 6 61
6695174 1984
2
A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma. 54 61
8882476 1996
3
Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes. 61
33585826 2021
4
Causal relationships between body mass index, smoking and lung cancer: Univariable and multivariable Mendelian randomization. 61
32914876 2021
5
Endotracheal, Endobronchial, and Vocal Cords Metastases From Lung Cancer Detected by 18F-FDG PET/CT. 61
33443947 2021
6
Poly(ADP-ribose) glycohydrolase silencing-mediated H2B expression inhibits benzo(a)pyrene-induced carcinogenesis. 61
33044785 2021
7
Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. 61
33429158 2021
8
RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. 61
33465699 2021
9
Use of a skin perforator flap pedicled by the intercostal muscle for reconstruction of a posterior cervical defect. 61
32067755 2021
10
A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis. 61
33549049 2021
11
Elevated NSD3 histone methylation activity drives squamous cell lung cancer. 61
33536620 2021
12
Detection Of Lung Cancer On Computed Tomography Using Artificial Intelligence Applications Developed By Deep Learning Methods And The Contribution Of Deep Learning To The Classification Of Lung Carcinoma. 61
33563200 2021
13
HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis. 61
33238795 2021
14
NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. 61
33077574 2021
15
Regression of Lung Squamous Cell Carcinoma after the Withdrawal of Cyclosporin A Combined with Pirfenidone Treatment in a Patient with Idiopathic Pulmonary Fibrosis. 61
33028767 2021
16
Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis. 61
33533494 2021
17
Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer. 61
32965722 2021
18
Albumin-to-alkaline phosphatase ratio: A novel prognostic index for patients with driver mutation-negative advanced non-small cell lung cancer. 61
33565707 2021
19
CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway. 61
33582208 2021
20
GenHITS: A network science approach to driver gene detection in human regulatory network using gene's influence evaluation. 61
33326867 2021
21
Fatal rupture of pulmonary artery pseudoaneurysm after thoracic radiation therapy against lung squamous cell carcinoma: A case report and literature review. 61
33598236 2021
22
[A Case of Squamous Cell Carcinoma of the Lung from Gastrointestinal Perforation Due to Small Intestinal Metastasis]. 61
33597383 2021
23
Histone Methyltransferase NSD3 Is a Lung Squamous Cell Carcinoma Driver. 61
33579784 2021
24
Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy. 61
33225417 2021
25
Prognostic significance of eight immune-related genes on survival in patients with lung squamous cell carcinoma. 61
33590774 2021
26
TFAP2A-induced SLC2A1-AS1 promotes cancer cell proliferation. 61
33580997 2021
27
Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma. 61
33348023 2021
28
Evaluation of the prognostic values of solute carrier (SLC) family 39 genes for patients with lung adenocarcinoma. 61
33535184 2021
29
Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index. 61
32950635 2021
30
CHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer. 61
33466316 2021
31
Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. 61
33365062 2021
32
ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer. 61
33408251 2021
33
Tumor-educated platelet SNORD55 as a potential biomarker for the early diagnosis of non-small cell lung cancer. 61
33474827 2021
34
Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient. 61
33506299 2021
35
Clinical research on the combined use of systemic chemotherapy and CT-guided radiofrequency ablation in treatment of lung cancer. 61
33417066 2021
36
Pathological and Prognostic Indications of the mdig Gene in Human Lung Cancer. 61
33423409 2021
37
CX3 CL1 promotes tumour cell by inducing tyrosine phosphorylation of cortactin in lung cancer. 61
33191645 2021
38
Zosteriform skin metastasis caused by retrograde lymphatic migration of metastatic squamous cell lung carcinoma. 61
33499850 2021
39
Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report. 61
33475256 2021
40
Systematic analysis using a bioinformatics strategy identifies SFTA1P and LINC00519 as potential prognostic biomarkers for lung squamous cell carcinoma. 61
33527016 2021
41
HEDGEHOG/GLI Modulates the PRR11-SKA2 Bidirectional Transcription Unit in Lung Squamous Cell Carcinomas. 61
33477943 2021
42
LncRNA CBR3-AS1 potentiates Wnt/β-catenin signaling to regulate lung adenocarcinoma cells proliferation, migration and invasion. 61
33422081 2021
43
Plakophilin-2 Promotes Lung Adenocarcinoma Development via Enhancing Focal Adhesion and Epithelial-Mesenchymal Transition. 61
33519235 2021
44
Investigation of Targeting Relationship between Micro-Rna-22 and Vegfr3 in Lung Squamous Cell Carcinoma. 61
32691705 2021
45
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. 61
33229301 2021
46
Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy. 61
33384062 2021
47
Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients. 61
33428598 2021
48
Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma. 61
33485313 2021
49
Gene expression profiles of the original tumors influence the generation of PDX models of lung squamous cell carcinoma. 61
33495573 2021
50
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma. 61
33391473 2021

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 329)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KRAS NM_004985.5(KRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
2 EGFR NM_005228.5(EGFR):c.2492G>A (p.Arg831His) SNV Pathogenic 560007 rs150036236 7:55259434-55259434 7:55191741-55191741
3 CDKN2A NM_000077.4(CDKN2A):c.194T>C (p.Leu65Pro) SNV Likely pathogenic 820351 rs1587332314 9:21971164-21971164 9:21971165-21971165
4 ALK NM_004304.5(ALK):c.4472A>G (p.Lys1491Arg) SNV Likely pathogenic 133474 rs1881420 2:29416481-29416481 2:29193615-29193615
5 ALK NM_004304.5(ALK):c.4587C>G (p.Asp1529Glu) SNV Likely pathogenic 133476 rs1881421 2:29416366-29416366 2:29193500-29193500
6 CDKN2A NM_000077.4(CDKN2A):c.292C>T (p.His98Tyr) SNV Likely pathogenic 419560 rs1064793953 9:21971066-21971066 9:21971067-21971067
7 PIK3CA NM_006218.4(PIK3CA):c.452T>C (p.Val151Ala) SNV Likely pathogenic 873163 3:178917577-178917577 3:179199789-179199789
8 ALK NM_004304.5(ALK):c.4381A>G (p.Ile1461Val) SNV Likely pathogenic 133472 rs1670283 2:29416572-29416572 2:29193706-29193706
9 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
10 TP53 NM_000546.5(TP53):c.641A>G (p.His214Arg) SNV Likely pathogenic 376615 rs1057519992 17:7578208-7578208 17:7674890-7674890
11 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
12 FBXW7 NM_001349798.2(FBXW7):c.1436G>T (p.Arg479Leu) SNV Likely pathogenic 376421 rs866987936 4:153247366-153247366 4:152326214-152326214
13 HRAS NM_005343.4(HRAS):c.37G>C (p.Gly13Arg) SNV Likely pathogenic 35554 rs104894228 11:534286-534286 11:534286-534286
14 FBXW7 NM_001349798.2(FBXW7):c.1513C>G (p.Arg505Gly) SNV Likely pathogenic 376423 rs149680468 4:153247289-153247289 4:152326137-152326137
15 NFE2L2 NM_006164.5(NFE2L2):c.235G>C (p.Glu79Gln) SNV Likely pathogenic 376465 rs1057519922 2:178098810-178098810 2:177234082-177234082
16 NFE2L2 NM_006164.5(NFE2L2):c.235G>A (p.Glu79Lys) SNV Likely pathogenic 376466 rs1057519922 2:178098810-178098810 2:177234082-177234082
17 TP53 NM_000546.5(TP53):c.838A>G (p.Arg280Gly) SNV Likely pathogenic 376658 rs753660142 17:7577100-7577100 17:7673782-7673782
18 FBXW7 NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln) SNV Likely pathogenic 376419 rs866987936 4:153247366-153247366 4:152326214-152326214
19 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys) SNV Likely pathogenic 376414 rs867384286 4:153249385-153249385 4:152328233-152328233
20 FBXW7 NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu) SNV Likely pathogenic 376417 rs1057519895 4:153249384-153249384 4:152328232-152328232
21 PTEN NM_000314.8(PTEN):c.389G>T SNV Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
22 PIK3CA NM_006218.4(PIK3CA):c.1625A>G (p.Glu542Gly) SNV Likely pathogenic 376475 rs1057519927 3:178936083-178936083 3:179218295-179218295
23 FBXW7 NM_001349798.2(FBXW7):c.1436G>C (p.Arg479Pro) SNV Likely pathogenic 376420 rs866987936 4:153247366-153247366 4:152326214-152326214
24 NFE2L2 NM_006164.5(NFE2L2):c.236A>T (p.Glu79Val) SNV Likely pathogenic 376467 rs1057519923 2:178098809-178098809 2:177234081-177234081
25 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely pathogenic 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
26 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Likely pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
27 TP53 NM_000546.5(TP53):c.839G>A (p.Arg280Lys) SNV Likely pathogenic 376657 rs121912660 17:7577099-7577099 17:7673781-7673781
28 FBXW7 NM_001349798.2(FBXW7):c.1435C>G (p.Arg479Gly) SNV Likely pathogenic 376422 rs747241612 4:153247367-153247367 4:152326215-152326215
29 NFE2L2 NM_006164.5(NFE2L2):c.85G>C (p.Asp29His) SNV Likely pathogenic 376461 rs1057519920 2:178098960-178098960 2:177234232-177234232
30 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro) SNV Likely pathogenic 376416 rs1057519895 4:153249384-153249384 4:152328232-152328232
31 PIK3CA NM_006218.4(PIK3CA):c.353G>A (p.Gly118Asp) SNV Likely pathogenic 156446 rs587777790 3:178917478-178917478 3:179199690-179199690
32 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
33 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Likely pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
34 PIK3CA NM_006218.4(PIK3CA):c.113G>T (p.Arg38Leu) SNV Likely pathogenic 376495 rs772110575 3:178916726-178916726 3:179198938-179198938
35 PIK3CA NM_006218.4(PIK3CA):c.112C>T (p.Arg38Cys) SNV Likely pathogenic 376493 rs749415085 3:178916725-178916725 3:179198937-179198937
36 TP53 NM_001276697.2(TP53):c.-27C>G SNV Likely pathogenic 376641 rs28934874 17:7578479-7578479 17:7675161-7675161
37 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Likely pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
38 FBXW7 NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys) SNV Likely pathogenic 69961 rs149680468 4:153247289-153247289 4:152326137-152326137
39 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser) SNV Likely pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
40 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu) SNV Likely pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
41 TP53 NM_000546.5(TP53):c.394A>C (p.Lys132Gln) SNV Likely pathogenic 376628 rs747342068 17:7578536-7578536 17:7675218-7675218
42 PIK3CA NM_006218.4(PIK3CA):c.3141T>G (p.His1047Gln) SNV Likely pathogenic 376481 rs1057519932 3:178952086-178952086 3:179234298-179234298
43 PIK3CA NM_006218.4(PIK3CA):c.317G>T (p.Gly106Val) SNV Likely pathogenic 376479 rs1057519930 3:178916930-178916930 3:179199142-179199142
44 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
45 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely pathogenic 13656 rs121913274 3:178936092-178936092 3:179218304-179218304
46 HRAS NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely pathogenic 180848 rs104894226 11:534285-534285 11:534285-534285
47 FBXW7 NM_001349798.2(FBXW7):c.1514G>T (p.Arg505Leu) SNV Likely pathogenic 376424 rs1057519896 4:153247288-153247288 4:152326136-152326136
48 FBXW7 NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser) SNV Likely pathogenic 376426 rs149680468 4:153247289-153247289 4:152326137-152326137
49 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys) SNV Likely pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
50 FBXW7 NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly) SNV Likely pathogenic 376418 rs867384286 4:153249385-153249385 4:152328233-152328233

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 46804)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 21
2 COSM101712070 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.3171G>C p.V1057= 2:135200405-135200405 21
3 COSM131775319 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1815G>C p.V605= 2:135200405-135200405 21
4 COSM87596300 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.3177G>C p.V1059= 2:135200405-135200405 21
5 COSM142228089 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522= 2:135200405-135200405 21
6 COSM142168947 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.-18G>C p.? 7:89218278-89218278 21
7 COSM92052275 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 21
8 COSM142179137 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3235C>T p.Q1079* 7:89336466-89336466 21
9 COSM142183562 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1361A>G p.K454R 7:89334592-89334592 21
10 COSM142180477 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1413G>T p.L471F 7:89334644-89334644 21
11 COSM142169111 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.494G>A p.C165Y 7:89333725-89333725 21
12 COSM142178407 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.734A>G p.N245S 7:89333965-89333965 21
13 COSM92062218 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 21
14 COSM92044981 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 21
15 COSM92017258 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 21
16 COSM92016873 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 21
17 COSM92047471 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 21
18 COSM88573896 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 21
19 COSM143615263 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.-93G>T p.? 2:184866420-184866420 21
20 COSM135196993 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.386G>A p.R129H 16:2002647-2002647 21
21 COSM137961812 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.386G>A p.R129H 16:2002647-2002647 21
22 COSM94776745 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 21
23 COSM131483085 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 21
24 COSM140721616 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.757C>T p.P253S 18:25226501-25226501 21
25 COSM94799739 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 21
26 COSM131506553 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 21
27 COSM140704568 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.274T>A p.C92S 18:25226984-25226984 21
28 COSM89756750 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 21
29 COSM144163369 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.779+33G>T p.? 7:57120351-57120351 21
30 COSM90068315 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 21
31 COSM106286350 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
32 COSM112397402 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
33 COSM123216142 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
34 COSM125618139 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
35 COSM124797288 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
36 COSM122109165 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
37 COSM86289413 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
38 COSM124886437 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 21
39 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 21
40 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 21
41 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 21
42 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 21
43 COSM101607526 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 21
44 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21
45 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21
46 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 21
47 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 21
48 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 21
49 COSM101586020 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 21
50 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain EMC10 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss CD44 Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP63 Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 TP53 PIK3CA KRAS FGFR2 EGFR
2
Show member pathways
12.55 TP53 PIK3CA KRAS FGFR2 EGFR
3
Show member pathways
12.45 TP53 PIK3CA KRAS FGFR2 EGFR
4
Show member pathways
12.4 TP53 TERC PIK3CA KRAS FGFR2 EGFR
5
Show member pathways
12.3 TP53 PIK3CA KRAS FGFR2 EGFR
6
Show member pathways
12.27 TP53 PIK3CA KRAS FGFR2 EGFR
7
Show member pathways
12.24 PIK3CA KRAS FGFR2 EGFR ALK
8
Show member pathways
12.23 TP53 PIK3CA KRAS FGFR2 EGFR ALK
9 12.22 TP53 TERC PIK3CA KRAS FGFR2 EGFR
10
Show member pathways
12.19 TP53 PIK3CA KRAS FGFR2 EGFR
11 12.14 TP53 PIK3CA KRAS EGFR
12
Show member pathways
12.04 TP53 PIK3CA KRAS FGFR2 EGFR
13
Show member pathways
11.71 PIK3CA KRAS EGFR
14 11.58 TP53 KRAS EGFR
15 11.29 KRAS FGFR2 EGFR
16 10.93 PIK3CA KRAS EGFR
17 10.87 TP53 PIK3CA KRAS FGFR2 EGFR
18 10.64 TP53 MEG3

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 liver development GO:0001889 9.33 PIK3CA KRAS EGFR
2 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.96 TP53 EGFR
3 positive regulation of kinase activity GO:0033674 8.8 FGFR2 EGFR ALK

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 FGFR2 EGFR ALK

Sources for Lung Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....